Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
Bottom Line: The most common adverse events were decreased lymphocyte count, decreased natural killer cell count, increased C-reactive protein, and pyrexia.Grade 3 adverse events (increased blood pressure, decreased lymphocyte count, and decreased platelet count) were observed in two or more patients.Furthermore, three patients showed long-term stable disease of more than 5 months.
Affiliation: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.Show MeSH
Related in: MedlinePlus
Mentions: All 13 unique core-needle biopsied specimens taken from tumor lesions in the liver were stained by both methods and were evaluated by using their respective scoring criteria. The representative GPC3-IHC features for both staining methods are shown in Figure 1(a) and all cases are shown in Figure S1. Twelve patients had a total GPC3 staining score of 7 or more by method 1, and 12 patients had positive clinical scores by method 2 (Fig. 1b). Both staining methods produced a similar staining pattern in the majority of specimens. The GPC3 staining score of method 1 was highly correlated with the clinical score of method 2 (Spearman's correlation coefficient, 0.76; P = 0.00255). Higher clinical scores appeared to be associated with increased H scores for both the membrane and cytoplasm in this limited number of samples (Fig. 1c,d).
Affiliation: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.